@article{9db3c9e3bd2f484e84c1edd5d995c054,
title = "Comment on “Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis”",
author = "Lebwohl, {Mark G.}",
note = "Funding Information: Disclosure: Dr Lebwohl is an employee of Mount Sinai, which receives research funds from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Kadmon, Leo Pharmaceuticals, MedImmune, Novartis, Pfizer, SCIderm, UCB, Ortho-dermatologics, and Vidac. He is also a consultant for Allergan, Almirall, Arcutis, Avotres, Birch Biomed, Boehringer-Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, LEO Pharma, Meiji, Menlo, Mitsubishi Pharma, NeuroDerm, Pfizer, Promius/Dr. Reddy, Theravance Biopharma, and Verrica. Funding sources: None.",
year = "2021",
month = dec,
doi = "10.1016/j.jaad.2019.05.081",
language = "English",
volume = "85",
pages = "e377",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",
}